Text Size

Statin and PAF in Patients With Pacemaker

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00201552
First received: September 12, 2005
Last updated: September 19, 2005
Last verified: September 2005
History of Changes
  Purpose

Statin could decrease AF burden


Condition Intervention
Paroxysmal Atrial Fibrillation
 Drug: Statin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Atorvastatin Decreases Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Taiwan University Hospital:

Detailed Description:

Statin could decrease AF burden in patients with PAF.

  Eligibility

Ages Eligible for Study:   20 Years to 90 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Patients with pacemaker

Exclusion Criteria:

  • Patients with hepatic dysfunction
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00201552

Contacts
Contact: Chia-Ti Tsai, MD 886-2-23123456 ext 5761 fang31@ms39.hinet.net

Locations
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan
Contact: Chia-Ti Tsai            
Principal Investigator: Chia-Ti Tsai, MD            
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Study Chair: Jiunn-Lee Lin, MD, PhD National Taiwan University Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00201552     History of Changes
Other Study ID Numbers: 930106
Study First Received: September 12, 2005
Last Updated: September 19, 2005
Health Authority: Taiwan: Department of Health

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
 Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Enzyme Inhibitors
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 22, 2013